Home Newsfeeds Keybanc Maintains Overweight on Helios Technologies, Raises Price Target to $74

Keybanc Maintains Overweight on Helios Technologies, Raises Price Target to $74

Keybanc analyst Jeffrey Hammond maintains Helios Technologies (NYSE:HLIO) with a Overweight and raises the price target from $71 to $74.

byBenzinga Newsdesk

February 28, 2023

1 minute read

Keybanc analyst Jeffrey Hammond maintains Helios Technologies (NYSE:HLIO) with a Overweight and raises the price target from $71 to $74.

Dow Edges Lower; US Current Account Deficit Widens In Q1

By Avi Kapoor

June 20, 9:42 AM

U.S. stocks traded mixed this morning, with the S&P 500 gaining around 0.1% on Thursday. Following the market…

GRDI

Credit Suisse Sees Boston Beer’s Q3 Margins Improving On Pricing Benefits

By Shivani Kumaresan

October 17, 1:28 PM

Credit Suisse analyst Kaumil Gajrawala reiterated an Outperform rating on the shares of Boston Beer Co (NYSE:SAM) and raised the price target…

SAM

SpaceX Launches ‘Starlink Aviation’ For In-Flight Connectivity, Elon Musk Says It’ll Feel Like ‘Accessing Internet At Home’

By Shanthi Rexaline

October 19, 4:34 AM

Elon Musk-owned SpaceX’s Starlink has launched a new service that will allow air travelers to stay connected while on a flight.

TSLA

Editas Medicine To Present Clinical Data From The RUBY And EdiTHAL Trials Of Reni-cel At The EHA 2024 Congress In June

By Benzinga Newsdesk

May 14, 10:10 AM

Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage gene editing company, today announced that two abstracts, including one oral presentation and one poster presentation, detailing clinical data from the RUBY and

EDIT

Keybanc Maintains Overweight on Helios Technologies, Raises Price Target to $74

Related Posts

Dow Edges Lower; US Current Account Deficit Widens In Q1

Credit Suisse Sees Boston Beer’s Q3 Margins Improving On Pricing Benefits

SpaceX Launches ‘Starlink Aviation’ For In-Flight Connectivity, Elon Musk Says It’ll Feel Like ‘Accessing Internet At Home’

Editas Medicine To Present Clinical Data From The RUBY And EdiTHAL Trials Of Reni-cel At The EHA 2024 Congress In June